Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced Cancer
- Interventions
- Drug: SGX523 Capsules
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- SGX Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00607399
- Locations
- 🇺🇸
Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸Premiere Oncology, Arizona, Scottsdale, Arizona, United States
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced Cancer
- Interventions
- Drug: SGX523 Capsules
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- SGX Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00606879
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Premier Onocology, California, Santa Monica, California, United States
Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 2
Terminated
- Conditions
- Leukemia, Myeloid, Acute
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2006-11-03
- Lead Sponsor
- SGX Pharmaceuticals, Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT00129948
- Locations
- 🇺🇸
New York Presbyterian Hospital-Cornell Campus, New York, New York, United States
🇺🇸Univ. of Florida, Baptist Cancer Center, Jacksonville, Florida, United States
🇺🇸USC-Norris Neuro-Oncology Program, Los Angeles, California, United States
Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)
Phase 1
Terminated
- Conditions
- Acute Myelogenous Leukemia
- First Posted Date
- 2005-03-01
- Last Posted Date
- 2008-01-17
- Lead Sponsor
- SGX Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00104468
- Locations
- 🇺🇸
Cornell Medical College, New York Presbyterian, New York, New York, United States
🇺🇸MD Anderson, Houston, Texas, United States
Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors
Phase 1
Terminated
- Conditions
- Neoplasms
- First Posted Date
- 2005-02-25
- Last Posted Date
- 2006-11-03
- Lead Sponsor
- SGX Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00104286
- Locations
- 🇺🇸
The Sydney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath